Remission is good - relapse is bad.

about

Remission is good - relapse is bad.

Item

http://www.wikidata.org/entity/Q49305200

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Remission is good - relapse is bad.

@en

Remission is good - relapse is bad.

@nl

type

Item

label

Remission is good - relapse is bad.

@en

Remission is good - relapse is bad.

@nl

prefLabel

Remission is good - relapse is bad.

@en

Remission is good - relapse is bad.

@nl

P1476

Remission is good - relapse is bad.

@en

P2860

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial

Measurable residual disease testing in acute myeloid leukaemia.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: inv

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.

Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.

P304

4-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2017.182667

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Paul S. Gaynon

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29290629

http://www.w3.org/2001/XMLSchema#string

P932

5777185

http://www.w3.org/2001/XMLSchema#string

Remission is good - relapse is bad.

about

Remission is good - relapse is bad.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932